Abstract
Neoadjuvant therapy (NAT) allows pre-operative tumor downstaging and evaluation of pathological response. Clinical trials have demonstrated benefit of using NAT in the context of locally advanced non-small cell cancer (NSCLC). However, NAT is not commonly employed around the world and data are lacking as to how to establish a NAT program for locally advanced resectable NSCLC. The aim of this study is to evaluate the evolution in care patterns for patients with resectable locally advanced NSCLC within a regionalized pulmonary oncology academic network and to assess the impact of transition towards a large-scale NAT program.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
